A randomized placebo controlled trial of vitamin E for alcoholic hepatitis

Journal of Hepatology

Volumn 40, Issue 1, 2004, Pages 40-46

  Mezey, Esteban ^a   Potter, James J ^a   Rennie Tankersley, Lynda ^a   Caballeria, Juan ^b   Pares, Albert ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aminoterminal peptide of type III procollagen; Hyaluronic acid; Nuclear factor B; Tocopherol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; GAMMA TOCOPHEROL; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTHROMBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; AMINO TERMINAL SEQUENCE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBROGENESIS; FOLLOW UP; HUMAN; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0347950972     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00476-8     Document Type: Article

References (35)

1. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307.
2. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo controlled trial. Gastroenterology 2000;119:1637-1648.
3. Reinke LA. Spin trapping evidence for alcohol-associated oxidative stress. Free Radic Biol Med 2002;32:953-957.
4. Letteron P, Duchatelle V, Berson A, Fromenty B, Fisch C, Degott C, et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers. Gut 1993;34:409-414.
5. Pratico D, Iuliano L, Basili S, Ferro D, Camastra C, Cordova C, et al. Enhanced lipid peroxidation in hepatic cirrhosis. J Investig Med 1998; 46:51-57.
6. Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr 1996;16:321-347.
7. Ferre N, Camps J, Prats E, Girona J, Gomez F, Heras M, et al. Impaired vitamin E status in patients with parenchymal liver cirrhosis: relationship with lipoprotein compositional alterations, nutritional factors, and oxidative susceptibility of plasma. Metabolism 2002;51: 609-615.
8. Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993;69:665-679.
9. Bjorneboe GEA, Johnsen J, Bjorneboe A, Marklund S, Skylv N, Hoiseth A, et al. Some aspects of antioxidant status in blood from alcoholics. Alcohol Clin Exp Res 1988;12:806-810.
10. de la Maza MP, Peterman M, Bunout D, Hirsch S. Effects of long term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995;14:192-196.
11. Wenzel G, Kuklinski B, Ruhlmann C, Ehrhardt D. Alkoholtoxische hepatitis - 'eine frei Radikale' assoziierte Erkrankung. Letalitatssenkung durch adjuvante Antioxidantientherapie. Innere Medizin 1993; 48:490-496.
12. Leevy CM, Sherlock S, Tygstrup N, Zetterman R. Diseases of the liver and biliary tract. Standardization of nomenclature, diagnostic criteria, and prognosis. International Hepatology Informatics Group. New York: Raven Press; 1994. p. 53-54.
13. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
14. Lankford TR, Jacobs-Stewart PH. Foundations of normal and therapeutic nutrition. New York: Johns Wiley & Sons; 1986. p. 236-237.
15. Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983;6:896-905.
16. Carithers Jr RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HF, et al. Methylprednisone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110: 685-690.
17. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ. Circulating antioxidant concentrations in children with inflammatory bowel disease. Am J Clin Nutr 1997;(65):1482-1488.
18. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976;15:212-216.
19. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983;132:6-13.
20. Potter JJ, Cheneval D, Dang CV, Resar LMS, Mezey E, Yang VW. The upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol dehydrogenase gene. J Biol Chem 1991;266: 15457-15463.
21. Vatassery GT, Bauer T, Dysken M. High dose of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 1999;70:793-801.
22. Muller G, Rahfeld B, Jannasch M. Malondialdehyd-Konzentration im Blutplasma von Patienten mit Leberkrankungen. Z Gesamte Inn Med 1992;47(Suppl.):263-265.
23. Suematsu T, Matsumura T, Sato N, Miyamoto T, Ooka T, Kamada T, Abe H. Lipid peroxidation in alcoholic liver disease in humans. Alcohol Clin Exp Res 1981;5:427-430.
24. Butcher GP, Rhodes JM, Walker R, Krasner N, Jackson MJ. The effect of antioxidant supplementation on the serum marker of free radical activity and abnormal serum biochemistry in alcoholic patients admitted for detoxification. J Hepatol 1993;19:105-109.
25. Hill DB, Barve S, Joshi-Barve S, McClain C. Increased monocyte nuclear factor-NF-κB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med 2000;135:387-395.
26. Mandrekar P, Catalano D, Szabo G. Alcohol-induced regulation on nuclear regulatory factor NF-κB in human monocytes. Alcohol Clin Exp Res 1997;21:988-994.
27. Dong Q, Kelkar S, Xiao Y, Joshi-Barve S, McClain CJ, Barve SS. Ethanol enhances TNF-α-inducible NF-κB activation and HIV-1-LTR transcription in CD4 + Jurkat T lymphocytes. J Lab Clin Med 2000;136:333-343.
28. Hill DB, Devalaraja R, Joshi-Barve S, Barve S, McClain CJ. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 1999;7:563-570.
29. 4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 1995;22: 1474-1481.
30. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R. Radioimmunoassay for type III procollagen peptide and its application in human liver disease. Eur J Clin Invest 1979;9: 451-459.
31. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993;342: 895-898.
32. Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996;24:1399-1403.
33. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42:558-563.
34. Manna Z, Guopel S, Minuk GY. Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Gastroenterology 1996;110:1150-1155.
35. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, et al. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in rat liver. FEBS Lett 1992;308:267-270.